Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (NYSE:JNJ) said Tuesday that it expects its 2024 operation sales growth to grow between 5% and 6% as its psoriasis drug Stelara faces competition in the United States. Ahead of a meeting with investors, the company guided 2024 adjusted operational earnings per share in the range of $10.55 to $10.75, representing growth of 7.3% at the midpoint.

J&J forecasts 2024 sales growth of up to 6%

MONTGOMERY, Ala.--(BUSINESS WIRE)--In a compelling new article published in Bloomberg Law, attorney Andy Birchfield, who leads the mass torts section at the Beasley Allen Law Firm, delves into the ongoing struggle for justice in the face of mounting evidence linking Johnson & Johnson's (NYSE: JNJ) talc products to devastating health issues, particularly ovarian cancer and mesothelioma. Birchfield, an advocate for consumers harmed by defective products, passionately outlines the challenges a.

Publication in Bloomberg Law: ‘A Third J&J Bankruptcy Attempt Won't Resolve Victims' Talc Claims' by Andy Birchfield

Johnson & Johnson   (NYSE:JNJ) is in focus this morning, after the pharma giant offered up its guidance for 2024 and beyond.

Dow Stock Eyes Key Trendline After Guidance Update

FDA grants Breakthrough Therapy Designation to J&J's (JNJ) TAR-200 for high-risk non-muscle-invasive bladder cancer based on data from the phase IIb SunRISe-1 study.

J&J's (JNJ) Bladder Cancer Drug Gets FDA's Breakthrough Tag

The pharmaceutical and medical-device company offered long-term targets at an investor meeting.

Johnson & Johnson Ticks Higher Following Guidance Release

Johnson & Johnson's stock JNJ, +0.32% was slightly higher premarket Tuesday, after the healthcare company set guidance for 2024 and for the longer term, ahead of an investor day at the New York Stock Exchange. The company said it expects 2024 sales to grow 5% to 6% and for adjusted EPS to range from $10.55 to $10.75, including the recently announced acquisition of medical tech company Laminar Inc. , which will shave 15 cents off earnings.

J&J's stock slightly higher as company offers guidance for 2024 and longer term

Johnson & Johnson on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara.

Johnson & Johnson forecasts as much as 6% sales growth in 2024

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the ‘Company') is hosting a meeting today with the investment community at the New York Stock Exchange to present the Company's overarching strategy, its diverse and robust Innovative Medicine and MedTech pipelines and long-term financial outlook. “Science and technology will advance human health more in the next decade than it has in the last century, leading to more effective and personalized treatment, earlier intervent.

Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review

Pfizer

Johnson & Johnson demonstrates better R&D efficiency and has a larger patent portfolio compared to Pfizer. JNJ's product pipeline in the Pharmaceutical segment has more late-stage developments, supporting its positive growth outlook. Pfizer has a stronger financial position for future M&A activities, but JNJ's acquisitions are more diversified and provide potential synergies.

Johnson & Johnson Vs. Pfizer: Better Pharma Stock?

Procter & Gamble

Warren Buffett - known for making successful investments in Dividend Kings over the years - recently sold two popular Dividend Kings. We look at why he may have made these sales. We also share a different high yielding Dividend King that we think looks very attractively priced at the moment.

Buffett Just Sold Dividend Kings Johnson & Johnson And Procter & Gamble - Buy This One Instead

Amazon

PepsiCo

Palantir Technologies

SoFi Technologies

Tesla

Taiwan Semiconductor Manufacturing

The economy is showing strong signs of improvement as we get into the holiday mood. Investment choices are many, but investors with a limited amount need to conduct thorough research.

The 7 Best Ways to Invest $1,000 in the Stock Market Now

Apple

Coca-Cola

Microsoft

After Alphabet introduced the Google Bard platform (NASDAQ: GOOGL), which ignited enthusiasm for artificial intelligence (AI), the technology has rapidly showcased its capabilities across diverse industries, including delivering valuable insights to investors.

Google Bard picks 5 stocks to buy in 2024

Amgen

Cisco Systems

Chevron

Dow Inc

Goldman Sachs

Merck

Verizon

Walgreens

Walmart

"The Dow [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.” – Dow Jones & Co. The highest-yield 10 stocks are December's Dogs of the Dow: KO, AMGN, CSCO, GS, IBM, CVX, DOW, MMM, VZ, and WBA. They only averaged a 4.92% annual yield, as December prices rose. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated December net gains ranged between 11.08%-44.04%, topped by WBA 11/30/23.

December Dogs Of The Dow: 3 Buyable, 5 Watchable

Buffett's Berkshire Hathaway sold all of its Johnson & Johnson shares in the recent quarter. This marks the billionaire investor's exit from the pharmaceutical industry.

Warren Buffett Just Closed His Position in This Dividend Giant. Should You?

Ares Capital

Bank of America

British American Tobacco

Mastercard

Main Street Capital

Realty Income Corp

Philip Morris

Royal Bank of Canada

Schwab US Dividend Equity ETF

AT&T

TCP Capital

In this article, I will demonstrate how you could build a diversified dividend portfolio that blends dividend income with dividend growth, aiming towards achieving an attractive Total Return. I will use The Dividend Income Accelerator Portfolio as an example, and will show that it already successfully balances dividend income with dividend growth, striving to maximize investor benefits. I will explain in greater detail how this portfolio reduces risk for investors, thereby enhancing the probability of reaching attractive investment returns.

How To Build A High-Potential Dividend Portfolio Combining Dividend Income With Dividend Growth

Automatic Data Processing

Albemarle

American Homes 4 Rent

Alexandria Real Estate Equities

Bristol-Myers

Caterpillar

Citizens Financial Group

Cigna

Cincinnati Financial

Deere & Company

Dollar General

EOG Resources

Diamondback Energy

Genuine Parts

Hershey

JPMorgan Chase & Co

Lennar

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields just over 3%, we present two other groups of five DGI stocks each, with the goal of moderate to high yields.

5 Relatively Secure And Cheap Dividend Stocks To Invest In - December 2023

News for Johnson & Johnson Stock (JNJ)